These strategies can also be combined with additional remote loading strategies for silicasomes and liposomes to deliver GSK3 and CXCR4 inhibitors, with additional impacts on the diversity of immune landscapes that appear in PDAC, triple-negative breast cancer, colon, and lung cancer. Here, CXCR4 is linked to triple-negative breast carcinoma.